Fierce Biotech1 min read
saveCellectis will shed 70% of workforce as part of in vivo pivot
Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
comments(0)
5-min edit window · permanent after that